Myrecordjournal.com reported that Alexion Pharmaceuticals (NYSE:ALXN) today announced its approval from the U.S. Food and Drug Administration to test out a new drug in preventing complications in patients who reject organ transplants, specifically targeting kidney transplant patients.
As quoted in the market news:

The drug, Soliris, is currently approved by the FDA to treat two extremely rare, life-threatening blood disorders, and is not approved in any country to prevent delayed graft function, or the failure of a transplanted organ to function properly in the patient’s body.

Read the full story in Myrecordjournal.com